Telix Highlights Presentations at Upcoming ASCO Genitourinary Cancers Symposium (ASCO GU 2024)

MELBOURNE, Australia, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces presentations featuring the Company’s theranostic programs at the upcoming American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2024) to be held in San Francisco, CA (US) from 25 – 27 January 2024.

Dr David N. Cade, Telix Group Chief Medical Officer, said, “We are pleased to present updates on our late-stage therapeutic programs for prostate and kidney cancer at ASCO GU 2024, the leading specialised event for GU cancer care worldwide.

“The ProstACT GLOBAL study of TLX591 (¹⁷⁷Lu rosopatamab tetraxetan) will be presented, the first Phase III trial to evaluate TLX591, our lead radio-antibody drug conjugate (rADC) therapy candidate in patients with PSMA-positive metastatic castrate-resistant prostate cancer (mCRPC).

“Data from the recently completed Phase I ProstACT SELECT study will also be showcased, confirming the clinical validity of Telix’s optimal fractionated dosing and product safety profile.¹ Both ProstACT studies are exploring TLX591 administered together with real-world standard of care, differentiating this program from other PSMA studies and reflecting Telix’s continued innovation in prostate cancer care and commitment to patient outcomes.

“Eric Jonasch MD, will present the STARLITE-1 investigator-initiated trial of Telix’s therapy candidate, TLX250 (¹⁷⁷Lu girentuximab), in combination with immunotherapy in clear cell renal cell carcinoma, the most common and aggressive form of kidney cancer.

“We look forward to seeing you at our booth to discuss Telix’s industry leading theranostic pipeline, our associated medical devices, and opportunities for collaboration.”

ASCO GU 2024 presentation details are listed below: 

Track: Prostate Cancer- Advanced | Prostate Cancer- Localized
Type: Trials in Progress Poster Session
Title: ProstACT SELECT: Safety, tolerability, and dosimetry of TLX591 with best standard of care in patients with PSMA-expressing metastatic castration-resistant prostate cancer
ClinicalTrials.gov ID: NCT04786847
Location: Level 1, West Hall | On Demand
Date and Time: January 25, 2024 | 11:30 AM – 1:00 PM (PT)
Presenter: Nat Lenzo MD, GenesisCare, AUSTRALIA 
Abstract: TPS253
Poster Bd: Q14 

Track: Prostate Cancer- Advanced | Prostate Cancer- Localized
Type: Trials in Progress Poster Session
Title: ProstACT GLOBAL: A Phase III study of best standard of care with and without TLX591 for patients with PSMA-expressing metastatic castration-resistant prostate cancer progressing despite prior treatment with a novel androgen axis drug